ClinicalTrials.gg
RecruitingNCT05276726Updated Aug 13, 2026

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

A Phase 1/2 interventional study of JAB 21822 in Non-small Cell Lung Cancer, sponsored by Allist Pharmaceuticals, Inc.. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
765th of 1,593
104 · median 100
Started
2022
with 169 others
Phase 1/2
160 of 1,880
83 open now
Primary completion
2027-08
later than 601 of 986 live
Registered
947th of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 765th largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 170 that started in 2022, is one of 160 in phase 1/2, reaches primary completion later than 601 of the 986 other live ones, and was the 947th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 during Dose Escalation phase and preliminary antitumor activity in patients with NSCLC with concurrent KRAS G12C mutant and STK11 mutant and KEAP wild type either treatment naïve or at least one line prior therapy for advance disease during the expansion phase..

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. documented, locally-advanced or NSCLC with KRAS p.G12C mutation identified through molecular testing.
  2. STK11 co-mutation and KEAP1 Wild-Type (local confirmation)
  3. Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC
  4. 0-1

Exclusion criteria

Exclusion Criteria:

  1. Has or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days
  2. Any severe and/or uncontrolled medical conditions
  3. Active infection requiring systemic treatment within 7 days
  4. Therapeutic radiation therapy within 3 weeks of study day 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Phase 1 ,Dose Exploration ,monotherapy

    Dose escalation of JAB21822 will be administered as monotherapy to determine the MTD and RP2D

    Drug: JAB 21822

  • Experimental
    Phase 2, Dose Expansion, Part1 monotherapy

    Part 1 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects with previously untreated advanced non-small cell lung cancer (NSCLC)

    Drug: JAB 21822

  • Experimental
    Phase 2 Dose Expansion, Part 2 monotherapy

    Part 2 dose expansion is to evaluate the safety and clinical activity of JAB-21822 at RP2D in subjects who had received at least one previous line of systemic therapy for NSCLC

    Drug: JAB 21822

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation phase Number of participants with dose limiting toxicities (DLTs)

    A DLT is defined as the clinically significant treatment-related adverse event or abnormal laboratory values assessment during the first 21 days of Cycle 1. It excludes adverse events (AEs) that are deemed clearly related to underlying disease, progression, or intercurrent illness.

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. Dose Escalation phase: Number of participants with adverse events

    Patients will be assessed for incidence and severity of AEs according to NCI-CTCAE 5.0 criteria

    Time frame: Up to 3 years

  3. Dose Expansion phase: Objective response rate (ORR)

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST v 1.1

    Time frame: Up to 3 years - from baseline to confirmed Progressive Disease per RECIST.

Secondary outcomes

  1. Dose Escalation phase: Objective response rate (ORR)

    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST v 1.1

    Time frame: Up to 3 years - from baseline to RECIST confirmed Progressive Disease

  2. Dose Escalation and Dose Expansion phase: Progression-free survival (PFS)

    PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per RECIST1.1 or death whichever occurs first

    Time frame: Up to 3 years

  3. Dose Escalation and Dose Expansion phase: Duration of response (DOR)

    DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to 3 years

  4. Dose Escalation and Dose Expansion phase: Disease Control Rate (DCR)

    DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) per RECIST v1.1

    Time frame: Up to 3 years

  5. Dose Escalation and Dose Expansion phase: Overall Survival (OS)

    Defined as time from first treatment to death by any cause

    Time frame: Up to 3 years

  6. Dose Escalation and Dose Expansion phase: Time to response (TTR)

    Defined as time from first treatment to first evidence of PR or CR

    Time frame: Up to 3 years

  7. Dose Expansion phase: Number of participants with adverse events

    Patients will be assessed for incidence and severity of adverse events (AEs) according to NCI-CTCAE criteria

    Time frame: Up to 3 years

  8. Dose Escalation and Dose Expansion phase: Plasma concentration (Cmax)

    Cmax of JAB-21822 will be measured by using plasma PK samples

    Time frame: Up to 3 Years

  9. Dose Escalation and Dose Expansion phase: Time to achieve Cmax (Tmax)

    Tmax of JAB-21822 will be measured by using plasma PK samples

    Time frame: Up to 3 Years

  10. Escalation and Dose Expansion phase:Area under the plasma concentration-time curve (AUC)

    AUC of JAB-21822 will be measured by using plasma PK samples

    Time frame: Up to 3 Years

07

Study locations

1 of 21 sites recruiting
  • Research site08
    Beijing, Beijing Municipality 100010, China
    Not yet recruiting
  • Research site09
    Beijing, Beijing Municipality 100010, China
    Not yet recruiting
  • Research site021
    Beijing, Beijing Municipality 100032, China
    Not yet recruiting
  • Research site02
    Beijing, Beijing Municipality 100089, China
    Not yet recruiting
  • Research site01
    Beijing, Beijing Municipality 100101, China
    Recruiting
    • Wang Jie Wang Jie M.D., M.D. · Contactzlhuxi@163.com · 010-87788029
  • Research site013
    Beijing, Beijing Municipality 101100, China
    Not yet recruiting
  • Research site010
    Chongqing, Chongqing Municipality 400000, China
    Not yet recruiting
  • Research site05
    Xiamen, Fujian 361000, China
    Not yet recruiting
  • Research site011
    Shenzhen, Guangdong 518000, China
    Not yet recruiting
  • Research site016
    Nanning, Guangxi 530000, China
    Not yet recruiting
  • Research site017
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
  • Research site018
    Harbin, Heilongjiang 150000, China
    Not yet recruiting
  • Research site04
    Zhengzhou, Henan 450000, China
    Not yet recruiting
  • Research site012
    Changsha, Hunan 410000, China
    Not yet recruiting
  • Research site015
    Changchun, Jilin 130000, China
    Not yet recruiting
  • Research site06
    Shenyang, Liaoning 110000, China
    Not yet recruiting
  • Research site07
    Shenyang, Liaoning 110000, China
    Not yet recruiting
  • Research site014
    Hohhot, Neimenggu 010000, China
    Not yet recruiting
  • Research site020
    Xi’an, Shanxi 710000, China
    Not yet recruiting
  • Research site03
    Hubei, Wuhan 430060, China
    Not yet recruiting
  • Research site019
    Hangzhou, Zhejiang 310000, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2027, 60 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 60 months is close to that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 11, 2022
StartActual
Aug 17, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05276726
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Aug 17, 2022
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd
Contact
zhenhua.gong@allist.com.cn
021-80423288
Wang Jie Wang Jie M.D.
Contact
zlhuxi@163.com
010-87788029

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecirasib

Start the discussion